Literature DB >> 8857324

Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients.

J Fujita1, I Yamadori, G Xu, S Hojo, K Negayama, H Miyawaki, Y Yamaji, J Takahara.   

Abstract

Between January 1988 and December 1992, 68 patients admitted to our Department of Internal Medicine with haematological malignancies or solid tumours showed colonization of the respiratory tract with Stenotrophomonas maltophilia. To characterize the significance of respiratory tract colonization by S. maltophilia, we retrospectively reviewed the medical records of the 68 patients colonized with this organism. Twenty-nine of these 68 patients developed pneumonia, with S. maltophilia being implicated in 10 cases. The majority of these 10 patients showed lobular infiltration on chest X-ray. Pleural effusion was observed in two (20%) of the 10 patients. All 68 strains of S. maltophilia were resistant to imipenem. Latamoxef was effective against 98 center dot 5% of strains, while minocycline was effective against 100% of strains. This report describes the clinical features of nosocomial S. maltophilia pneumonia in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857324     DOI: 10.1016/s0954-6111(96)90242-5

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  20 in total

1.  Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia.

Authors:  M B Avison; C S Higgins; C J von Heldreich; P M Bennett; T R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

3.  Clinical characteristics and outcomes of patients with pleural infections due to Stenotrophomonas maltophilia at a medical center in Taiwan, 2004-2012.

Authors:  M-R Lee; H-C Wang; C-Y Yang; C-K Lin; H-Y Kuo; J-C Ko; W-H Sheng; L-N Lee; C-J Yu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-24       Impact factor: 3.267

Review 4.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 5.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 6.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

Review 7.  Community-acquired Stenotrophomonas maltophilia infections: a systematic review.

Authors:  M E Falagas; A C Kastoris; E K Vouloumanou; G Dimopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-18       Impact factor: 3.267

8.  Molecular Insight into Gene Response of Diorcinol- and Rubrolide-Treated Biofilms of the Emerging Pathogen Stenotrophomonas maltophilia.

Authors:  Mirja Gudzuhn; Ifey Alio; Raphael Moll; Jessica de Vries; Jacob Boehlich; Maik Assmann; Jasmin Janneschütz; Nina Schützenmeister; Axel Himmelbach; Anja Poehlein; Rolf Daniel; Wolfgang R Streit
Journal:  Microbiol Spectr       Date:  2022-04-26

9.  Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia.

Authors:  Doroti de Oliveira-Garcia; Monique Dall'Agnol; Mónica Rosales; Ana C G S Azzuz; Marina B Martinez; Jorge A Girón
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

10.  Treatment refractory Stenotrophomonas maltophilia bacteraemia and pneumonia in a COVID-19-positive patient.

Authors:  Zachary Pek; Maria Gabriela Cabanilla; Shozab Ahmed
Journal:  BMJ Case Rep       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.